The Role of the Blood Brain Barrier in Neurodegenerative Disorders and their Treatment
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Neurodegenerative disorders represent a major medical challenge that is set to increase substantially in the decades ahead with the massive increase in the number of people in the world aged 65 or more. Neuroprotective therapeutics have the potential to play a key role in helping manage this growing global burden of long-term neurological care. However, neuropharmaceutical research is associated with significant challenges including: 1) the complexity of the brain (the cause of the majority of neurodegenerative disorders remains unknown); 2) the liability of central nervous system (CNS) drugs to cause CNS side effects (which limits their use); and 3) the requirement of neuropharmaceuticals to cross the blood-brain barrier (BBB). The BBB itself also plays a key role in most (if not all) neurodegenerative disorders since BBB dysfunction inevitably leads to inflammatory change including the movement of immune cells and immune mediators into the brain, which then contribute to the process of neurodegeneration. This review focuses on the role of the BBB in both neurodegenerative disorders and neuropharmaceutical research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure and function of the blood–brain barrier
Abbott, N. J., Patabendige, A. A. K., Dolman, D. E. M., Yusof, S. R., & Begley, D. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.030 · Cited by 5,185
The epidemiology of traumatic brain injury: a review
Bruns, J., & Hauser, W. A. (2003) · Epilepsia · doi:10.1046/j.1528-1157.44.s10.3.x · Cited by 1,271 · cited 1×
“can occur at any age, it is males aged 15 to 24 that are most commonly affected [32].”
Microglial Activation and Chronic Neurodegeneration
Lull, M. E., & Block, M. L. (2010) · Neurotherapeutics · doi:10.1016/j.nurt.2010.05.014 · Cited by 1,047 · cited 1×
“1 and oxidative stress, BBB dysfunction, and neuroinflammation set up a further train of linked changes that set up a positive feedback loop that exacerbates neurodegenerative change [8, 87, 88].”
Review Article: Genetics of Alzheimer Disease
Bekris, L. M., Yu, C.-E., Bird, T. D., & Tsuang, D. W. (2010) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988710383571 · Cited by 1,029
Fisniku, L. K., Brex, P. A., Altmann, D. R., Miszkiel, K. A., Benton, C. E., Lanyon, R., Thompson, A. J., & Miller, D. H. (2008) · Brain · doi:10.1093/brain/awm329 · Cited by 897
Parkinson’s disease: genetics and pathogenesis
Shulman, J. M., De Jager, P. L., & Feany, M. B. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130242 · Cited by 801
The blood-brain barrier and immune function and dysfunction
Banks, W. A., & Erickson, M. A. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.031 · Cited by 523 · cited 2×
“2) [7, 8].”
Habgood, M. D., Bye, N., Dziegielewska, K. M., Ek, C. J., Lane, M. A., Potter, A., Morganti‐Kossmann, C., & Saunders, N. R. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05275.x · Cited by 220
Vos, C. M. P., Geurts, J. J. G., Montagne, L., van Haastert, E. S., Bö, L., van der Valk, P., Barkhof, F., & de Vries, H. E. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.06.012 · Cited by 188
Cited by
Griep, L. M., Wolbers, F., de Wagenaar, B., ter Braak, P. M., Weksler, B. B., Romero, I. A., Couraud, P. O., Vermes, I., van der Meer, A. D., & van den Berg, A. (2013) · Biomedical Microdevices · doi:10.1007/s10544-012-9699-7 · Cited by 537
Cano, A., Sánchez-López, E., Ettcheto, M., López-Machado, A., Espina, M., Souto, E. B., Galindo, R., Camins, A., García, M. L., & Turowski, P. (2020) · Nanomedicine · doi:10.2217/nnm-2019-0443 · Cited by 144
Gonzalez-Carter, D., Liu, X., Tockary, T. A., Dirisala, A., Toh, K., Anraku, Y., & Kataoka, K. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2002016117 · Cited by 127
Poudel, P., & Park, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040835 · Cited by 124
In vitro micro-physiological models for translational immunology
Ramadan, Q., & Gijs, M. A. M. (2015) · Lab on a Chip · doi:10.1039/c4lc01271b · Cited by 41
Metadata
- Authors
- Palmer, A. M.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2011-05-30
- Volume
- 24
- Issue
- 4
- Pages
- 643-656
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1575015788
- Cited by
- 85
- References
- 9
- FWCI
- 2.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Role of the Blood Brain Barrier in Neurodegenerative Disorders and their Treatment. https://app.cochat.ai/papers/10.3233/jad-2011-110368
- The paper
- Palmer, A. M. (2011). The Role of the Blood Brain Barrier in Neurodegenerative Disorders and their Treatment. Journal of Alzheimer’s Disease. https://doi.org/10.3233/jad-2011-110368
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.